WallStSmart

Vodafone Group PLC ADR (VOD)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vodafone Group PLC ADR generates 223% more annual revenue ($38.78B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs -11.4%. VOD appears more attractively valued with a PEG of 0.61. VRTX earns a higher WallStSmart Score of 66/100 (B-).

VOD

Buy

51

out of 100

Grade: C-

Growth: 6.0Profit: 3.5Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: -0.58

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for VOD.

VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VOD2 strengths · Avg: 8.0/10
PEG RatioValuation
0.618/10

Growing faster than its price suggests

Free Cash FlowQuality
$2.05B8/10

Generating 2.0B in free cash flow

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

VOD4 concerns · Avg: 1.8/10
Return on EquityProfitability
-6.6%2/10

ROE of -6.6% — below average capital efficiency

EPS GrowthGrowth
-15.4%2/10

Earnings declined 15.4%

Altman Z-ScoreHealth
-0.582/10

Distress zone — elevated risk

Profit MarginProfitability
-11.4%1/10

Currently unprofitable

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : VOD

The strongest argument for VOD centers on PEG Ratio, Free Cash Flow. PEG of 0.61 suggests the stock is reasonably priced for its growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : VOD

The primary concerns for VOD are Return on Equity, EPS Growth, Altman Z-Score.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

VOD profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.

VOD carries more volatility with a beta of 0.34 — expect wider price swings.

VRTX is growing revenue faster at 9.5% — sustainability is the question.

VOD generates stronger free cash flow (2.0B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 51/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Vodafone Group PLC ADR

COMMUNICATION SERVICES · TELECOM SERVICES · USA

Vodafone Group Plc is engaged in telecommunications services in Europe and internationally. The company is headquartered in Newbury, the United Kingdom.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?